Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition

The relation between tau, amyloid and cognition has yet to be fully defined. Using flortaucipir (18F-AV-1451) PET tau imaging in patients with varying amyloid and cognitive status, Pontecorvo et al. suggest that development of tau beyond the mesial temporal lobe is associated with, and may be dependent on, amyloid accumulation.

[1]  Nick C Fox,et al.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.

[2]  David S. Miller,et al.  Tau: From research to clinical development , 2016, Alzheimer's & Dementia.

[3]  Keith A. Johnson,et al.  Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly , 2016, Neurology.

[4]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[5]  W. Klunk,et al.  [F‐18]AV‐1451 positron emission tomography retention in choroid plexus: More than “off‐target” binding , 2016, Annals of neurology.

[6]  Yi Su,et al.  The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. , 2016, Brain : a journal of neurology.

[7]  Hanna Cho,et al.  Tau PET in Alzheimer disease and mild cognitive impairment , 2016, Neurology.

[8]  W. Jagust,et al.  Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351 , 2016, PloS one.

[9]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[10]  Yi Su,et al.  Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease , 2016, Science Translational Medicine.

[11]  M. Mintun,et al.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[12]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[13]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[14]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[15]  C. Jack,et al.  Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study , 2016, The Lancet Neurology.

[16]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[17]  Andrea Bergmann,et al.  Statistical Parametric Mapping The Analysis Of Functional Brain Images , 2016 .

[18]  P. Baatsen,et al.  Heterotypic seeding of Tau fibrillization by pre-aggregated Abeta provides potent seeds for prion-like seeding and propagation of Tau-pathology in vivo , 2016, Acta Neuropathologica.

[19]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[20]  Mark A. Mintun,et al.  A Semiautomated Method for Quantification of F 18 Florbetapir PET Images , 2015, The Journal of Nuclear Medicine.

[21]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[22]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[23]  I. Dewachter,et al.  Models of β-amyloid induced Tau-pathology: the long and “folded” road to understand the mechanism , 2014, Molecular Neurodegeneration.

[24]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[25]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.

[26]  Abbas Ali Mahdi,et al.  Therapeutics of Alzheimer's disease: Past, present and future , 2014, Neuropharmacology.

[27]  W. Noble,et al.  A role for tau at the synapse in Alzheimer's disease pathogenesis , 2014, Neuropharmacology.

[28]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. , 2014, Journal of Alzheimer's disease : JAD.

[29]  D. Holtzman,et al.  Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.

[30]  Gabriel Gold,et al.  Alzheimer disease therapy—moving from amyloid-β to tau , 2013, Nature Reviews Neurology.

[31]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[32]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[33]  H. Arai,et al.  Novel 18F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease , 2013, The Journal of Nuclear Medicine.

[34]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[35]  David J. Fleet,et al.  Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study. , 2012, Journal of Alzheimer's disease : JAD.

[36]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[37]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[38]  L. Grinberg,et al.  Neuropathologic features associated with Alzheimer disease diagnosis , 2011, Neurology.

[39]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[40]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[41]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[42]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[43]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[44]  C. Almli,et al.  Unbiased nonlinear average age-appropriate brain templates from birth to adulthood , 2009, NeuroImage.

[45]  M. Staufenbiel,et al.  Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice , 2007 .

[46]  Peter T Nelson,et al.  Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort: Neuritic Plaques and Neurofibrillary Tangles "Do Count" When Staging Disease Severity , 2007, Journal of neuropathology and experimental neurology.

[47]  Karl J. Friston,et al.  Statistical parametric mapping , 2013 .

[48]  M. Staufenbiel,et al.  Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. , 2007, The American journal of pathology.

[49]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[50]  K. Davis,et al.  Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease , 2006, Neurology.

[51]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[52]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[53]  W. Markesbery,et al.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the Nun Study , 2002, Annals of neurology.

[54]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[55]  Mark S. Shearman,et al.  Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .

[56]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[57]  J. Morrison,et al.  Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. , 1994, Cerebral cortex.

[58]  N. Cairns,et al.  Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms , 1992, Neuron.

[59]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Alistair Burns,et al.  Observations on the brains of demented old people. B.E. Tomlinson, G. Blessed and M. Roth, Journal of the Neurological Sciences (1970) 11, 205–242; (1968) 7, 331–356 , 1997 .

[61]  M. Kidd.  Paired Helical Filaments in Electron Microscopy of Alzheimer's Disease , 1963, Nature.